ArticleEuropean radiology2026
Baseline CT imaging parameters predicting overall and progression-free survival for patients with pulmonary metastases from soft tissue and bone sarcoma.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe lung is the most frequent metastatic site in soft tissue and bone sarcoma, yet CT imaging predictors of survival remain underexplored. Hence, the aim of this study was to evaluate baseline CT imaging predictors for overall survival (OS) and progression-free survival (PFS) in patients with pulmonary metastases from soft tissue and bone sarcoma. MATERIALS AND
methodsConsecutive patients treated from 2016 to 2021 were screened; those without lung metastases, systemic therapy, baseline CT imaging, or with prior lung surgery were excluded. Tumor burden (long axis, volume) and number of pulmonary lesions were assessed at baseline CT imaging and tested for OS and PFS. Significant univariate predictors were entered into multivariate models and reported as hazard ratios (HR).
resultsIn the 100 included patients, median OS was 22.1 months, and median PFS was 5.8 months. Tumor burden parameters were not predictive of OS nor PFS (HR 0.724-1.354, p = 0.265-0.975). The number of pulmonary lesions was prognostic, with ≥ 5 lesions predicting shorter OS in univariate (HR 1.709, 95% CI: 1.013-2.881, p = 0.033) and multivariate analysis (HR 3.478, 95% CI: 1.509-8.302, p = 0.004). For PFS, ≥ 5 lesions were significant in univariate analysis (HR 1.741, 95% CI: 1.113-2.723, p = 0.011) but not in multivariate analysis (HR 1.530, 95% CI: 0.395-7.391, p = 0.555).
conclusionAt baseline, CT imaging of patients with soft tissue and bone sarcoma, the number of pulmonary lesions independently predicted OS, whereas tumor burden showed no prognostic value. No imaging parameter independently predicted PFS. KEY POINTS: Question Which baseline CT imaging parameters best predict overall and PFS in patients with pulmonary metastases from soft tissue and bone sarcoma? Findings At baseline, CT imaging, pulmonary lesion count independently predicted OS, while pulmonary tumor burden was not prognostic. No imaging parameter independently predicted PFS. Clinical relevance Baseline CT imaging assessment of the number of pulmonary lesions provides prognostic information and may inform treatment decisions in patients with soft tissue and bone sarcoma.
Indexed as
Identifiers
41483204What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.